Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Neboglamine

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Neboglamine
Clinical data
Other namesNebostinel;N-(4,4-Dimethylcyclohexyl)-L-α-glutamine
ATC code
  • None
Identifiers
  • (4S)-4-Amino-5-[(4,4-dimethylcyclohexyl)amino]-5-oxopentanoic acid
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
ECHA InfoCard100.162.081Edit this at Wikidata
Chemical and physical data
FormulaC13H24N2O3
Molar mass256.346 g·mol−1
3D model (JSmol)
  • CC1(CCC(CC1)NC(=O)C(CCC(=O)O)N)C
  • InChI=1S/C13H24N2O3/c1-13(2)7-5-9(6-8-13)15-12(18)10(14)3-4-11(16)17/h9-10H,3-8,14H2,1-2H3,(H,15,18)(H,16,17)/t10-/m0/s1
  • Key:VCRGLZYPNNAVRP-JTQLQIEISA-N

Neboglamine (INNTooltip International Nonproprietary Name) (developmental code namesCR-2249,XY-2401), formerly known asnebostinel, is apositive allosteric modulator of theglycine site of theNMDA receptor which is under investigation for Rottapharm for the treatment ofschizophrenia andcocaine dependence.[1][2][3][4][5][6] It showscognition- andmemory-enhancing effects inanimal models.[7][8][9] As of June 2015, it is inphase IIclinical trials for both schizophrenia and cocaine abuse.[10]

See also

[edit]

References

[edit]
  1. ^Chiusaroli R, Garofalo P, Espinoza S, Neri E, Caselli G, Lanza M (May 2010). "Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat".Pharmacological Research.61 (5):430–6.doi:10.1016/j.phrs.2009.12.010.PMID 20045056.
  2. ^Kantrowitz J, Javitt DC (March 2012)."Glutamatergic transmission in schizophrenia: from basic research to clinical practice".Current Opinion in Psychiatry.25 (2):96–102.doi:10.1097/YCO.0b013e32835035b2.PMC 5224527.PMID 22297716.
  3. ^"Drug Development in Schizophrenia: Summary and Table".Pharmaceutical Medicine.28 (5):265–271. 2014.doi:10.1007/s40290-014-0070-6.ISSN 1178-2595.S2CID 8513976.
  4. ^Santangelo RM, Acker TM, Zimmerman SS, Katzman BM, Strong KL, Traynelis SF, Liotta DC (November 2012)."Novel NMDA receptor modulators: an update".Expert Opinion on Therapeutic Patents.22 (11):1337–52.doi:10.1517/13543776.2012.728587.PMC 3677696.PMID 23009122.
  5. ^Zink M, Correll CU (May 2015). "Glutamatergic agents for schizophrenia: current evidence and perspectives".Expert Review of Clinical Pharmacology.8 (3):335–52.doi:10.1586/17512433.2015.1040393.PMID 25916667.S2CID 39547774.
  6. ^Köster LS, Carbon M, Correll CU (December 2014). "Emerging drugs for schizophrenia: an update".Expert Opinion on Emerging Drugs.19 (4):511–31.doi:10.1517/14728214.2014.958148.PMID 25234340.S2CID 42729570.
  7. ^Garofalo P, Colombo S, Lanza M, Revel L, Makovec F (December 1996)."CR 2249: a new putative memory enhancer. Behavioural studies on learning and memory in rats and mice".The Journal of Pharmacy and Pharmacology.48 (12):1290–7.doi:10.1111/j.2042-7158.1996.tb03938.x.PMID 9004193.S2CID 34902435.
  8. ^Lanza M, Bonnafous C, Colombo S, Revel L, Makovec F (August 1997). "Characterization of a novel putative cognition enhancer mediating facilitation of glycine effect on strychnine-resistant sites coupled to NMDA receptor complex".Neuropharmacology.36 (8):1057–64.doi:10.1016/S0028-3908(97)00092-0.PMID 9294970.S2CID 11958361.
  9. ^Lanza M, Makovec F (1997). "Cognition Enhancing Profile of CR 2249, a New NMDA-Glycine Site Modulator".CNS Drug Reviews.3 (3):245–259.doi:10.1111/j.1527-3458.1997.tb00326.x.ISSN 1080-563X.
  10. ^"Neboglamine".AdisInsight. Retrieved2015-06-10.

External links

[edit]
AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
KARTooltip Kainate receptor
NMDARTooltip N-Methyl-D-aspartate receptor


Stub icon

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Neboglamine&oldid=1184108121"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp